(90 days)
Not Found
No
The device description and performance studies focus on the physical properties and mechanical performance of a barbed suture, with no mention of AI or ML capabilities.
No
The device is a surgical suture used for soft tissue approximation, not a device intended for therapy or treatment of a disease or condition.
No
This device is a surgical suture (specifically, a tissue control device) used for soft tissue approximation, not for diagnosing medical conditions. Its function is to hold tissues together, not to identify or monitor them.
No
The device description clearly outlines a physical, absorbable suture with barbs and needles, which is a hardware component, not software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is "soft tissue approximation where use of an absorbable suture is appropriate." This describes a surgical procedure performed directly on the patient's body.
- Device Description: The description details a surgical suture with barbs and needles, designed for physically joining tissue.
- Lack of IVD Characteristics: There is no mention of the device being used to examine specimens (like blood, urine, or tissue samples) in vitro (outside the body) to provide information for diagnosis, monitoring, or screening.
IVD devices are used to perform tests on samples taken from the body to provide diagnostic information. This device is a surgical tool used in vivo (within the body) for tissue repair.
N/A
Intended Use / Indications for Use
STRATAFIX™ Spiral MONOCRYL™ Plus Bidirectional Knotless Tissue Control Device is indicated for soft tissue approximation where use of an absorbable suture is appropriate.
Product codes
GAM
Device Description
The STRATAFIX™ Spiral MONOCRYL™ Plus Bidirectional Knotless Tissue Control Device is an antibacterial monofilament, synthetic absorbable device prepared from a copolymer of glycolide and s-caprolactone. The device contains IRGACARE®* MP (triclosan), a broad spectrum antibacterial agent, at no more than 2360 mug/m. The device is available in a dyed and undyed version. The pigment for the dyed version is D&C Violet No. 2. Poliglecaprone 25 copolymer has been found to be nonpyrogenic and elicits only a slight tissue reaction during absorption.
The STRATAFIX™ Spiral MONOCRYL™ Plus Knotless Tissue Control Bidirectional Device Design consists of barbed suture material, armed with a surgical needle on each end. The device also contains an unbarbed center transition zone that facilitation of the device use. The STRATAFIX™ Spiral MONOCRYL™ Plus Device barbs allow for tissue approximation without the need to tie surgical knots.
While the formation of barbs in the STRATAFIX™ Spiral MONOCRYL™ Plus Bidirectional Device reduces the tensile strength relative to non-barbed suture material of the same size, tying of knots in non-barbed suture materials also reduces their effective strength. For this reason, the strength of the STRATAFIX™ Spiral MONOCRYL™ Plus Bidirectional Device can be compared to USP knot strength of non-barbed sutures. The actual diameter of the non-barbed section fiber is one size greater than the designated size with a maximum overage of 0.1 mm.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
soft tissue
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Prescription Use
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non-clinical laboratory performance testing was performed demonstrating that STRATAFIX™ Spiral MONOCRYL™ Plus Bidirectional Knotless Tissue Control Device conforms to the current USP Monograph for absorbable surgical sutures, except for diameter. The testing was performed in accordance with FDA's Guidance Document: "Class II Special Controls Guidance Document: Surgical Sutures" issued on June 3, 2003. Bench testing evaluated: Suture Diameter, Needle Attachment Strength, Tensile Strength, In Vitro Breaking Strength, and Ex Vivo Wound Closure Strength.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 878.4493 Absorbable poly(glycolide/l-lactide) surgical suture.
(a)
Identification. An absorbable poly(glycolide/l-lactide) surgical suture (PGL suture) is an absorbable sterile, flexible strand as prepared and synthesized from homopolymers of glycolide and copolymers made from 90 percent glycolide and 10 percent l-lactide, and is indicated for use in soft tissue approximation. A PGL suture meets United States Pharmacopeia (U.S.P.) requirements as described in the U.S.P. “Monograph for Absorbable Surgical Sutures;” it may be monofilament or multifilament (braided) in form; it may be uncoated or coated; and it may be undyed or dyed with an FDA-approved color additive. Also, the suture may be provided with or without a standard needle attached.(b)
Classification. Class II (special controls). The special control for this device is FDA's “Class II Special Controls Guidance Document: Surgical Sutures; Guidance for Industry and FDA.” See § 878.1(e) for the availability of this guidance document.
0
Image /page/0/Picture/0 description: The image shows the logos of the Department of Health & Human Services and the Food and Drug Administration (FDA). The Department of Health & Human Services logo is on the left, and the FDA logo is on the right. The FDA logo is a blue square with the letters "FDA" in white, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue.
December 18, 2019
Ethicon, Inc Eleanor Zhou Regulatory Affairs Specialist Route 22 West, P.O. Box 151 Somerville, New Jersey 00876-0151
Re: K192580
Trade/Device Name: STRATAFIX Spiral Monocryl, Plus Bidirectional Knotless Tissue Control Device Regulation Number: 21 CFR 878.4493 Regulation Name: Absorbable Poly(Glycolide/L-Lactide) Surgical Suture Regulatory Class: Class II Product Code: GAM Dated: September 18, 2019 Received: September 19, 2019
Dear Eleanor Zhou:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
1
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-
combination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely.
Cindy Chowdhury, Ph.D., M.B.A. Acting Assistant Director DHT4B: Division of Infection Control and Plastic Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K192580
Device Name
STRATAFIX™ Spiral MONOCRYL™ Plus Bidirectional Knotless Tissue Control Device
Indications for Use (Describe)
STRATAFIX™ Spiral MONOCRYL™ Plus Bidirectional Knotless Tissue Control Device is indicated for soft tissue approximation where use of an absorbable suture is appropriate.
Type of Use (Select one or both, as applicable)
| Prescription Use (Part 21 CFR 801 Subpart D) |
|---|
| Over The Counter Use (21 CFR 801 Subpart D) |
|X Prescription Use (Part 21 CFR 801 Subpart D)
|_ | Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) Summary
| Submitter: | Ethicon Inc. a Johnson & Johnson company
P.O. Box 151
Route 22 West
Somerville, NJ 08876-0151
USA |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------|
| Contact Person: | Eleanor Zhou
Ethicon, Inc. a Johnson & Johnson company
Ph: (908) 218-3198
Fax: (908) 218-2595
e-mail: ezhou2@its.jnj.com |
| 510(k) Number: | K192580 |
| Date Prepared: | December 16, 2019 |
| Device Trade Name: | STRATAFIX™ Spiral MONOCRYL™ Plus Bidirectional
Knotless Tissue Control Device |
| Device Common Name: | Suture, Surgical, Absorbable, Polyglcolic Acid |
| Class: | II |
| Classification Name: | Suture, Absorbable, Synthetic, Polyglcolic Acid
(21 CFR 878.4493) |
| Product Code: | GAM |
| Predicate Device | 510(k) Number |
|---|---|
| STRATAFIXTM Spiral MONOCRYLTM Plus Knotless Tissue Control Device | |
| (Primary) | K182873 |
| QuillTM Self-Retaining System (SRS) comprised of MONODERMTM | |
| (Additional) | K072028 |
4
Device Description:
The STRATAFIX™ Spiral MONOCRYL™ Plus Bidirectional Knotless Tissue Control Device is an antibacterial monofilament, synthetic absorbable device prepared from a copolymer of glycolide and s-caprolactone. The device contains IRGACARE®* MP (triclosan), a broad spectrum antibacterial agent, at no more than 2360 µg/m. The device is available in a dyed and undyed version. The pigment for the dyed version is D&C Violet No. 2. Poliglecaprone 25 copolymer has been found to be nonpyrogenic and elicits only a slight tissue reaction during absorption.
The STRATAFIX™ Spiral MONOCRYL™ Plus Knotless Tissue Control Bidirectional Device Design consists of barbed suture material, armed with a surgical needle on each end. The device also contains an unbarbed center transition zone that facilitation of the device use. The STRATAFIX™ Spiral MONOCRYL™ Plus Device barbs allow for tissue approximation without the need to tie surgical knots.
While the formation of barbs in the STRATAFIX™ Spiral MONOCRYL™ Plus Bidirectional Device reduces the tensile strength relative to non-barbed suture material of the same size, tying of knots in non-barbed suture materials also reduces their effective strength. For this reason, the strength of the STRATAFIX™ Spiral MONOCRYL™ Plus Bidirectional Device can be compared to USP knot strength of non-barbed sutures. The actual diameter of the non-barbed section fiber is one size greater than the designated size with a maximum overage of 0.1 mm.
The USP and EU Pharmacopoeia sizes of the STRATAFIX™ Spiral MONOCRYL™ Plus Bidirectional Device are further defined in Table 1.
| USP DEVICE
SIZE
DESIGNATION | | EU
PHARMACOPOEIA
DEVICE SIZE
(Metric / Ph. Eur.)
DESIGNATION | STRATAFIX™ Spiral MONOCRYL™
Plus Bidirectional | |
|-----------------------------------|-----|--------------------------------------------------------------------------|----------------------------------------------------------|--|
| 0 | 3.5 | 0 | 3.5 | |
| 2-0 | 3 | 2-0 | 3 | |
| 3-0 | 2 | 3-0 | 2 | |
| 4-0 | 1.5 | 4-0 | 1.5 | |
Table 1. Diameter Comparison
TENSILE STRENGTH
STRATAFIX™ Spiral MONOCRYL™ Plus Bidirectional Device straight tensile strength meets the knot tensile strength for a USP and EU Pharmacopoeia poliglecaprone 25 device of the equivalent size as shown in Table 2.
5
| USP DEVICE
SIZE
DESIGNATION | EU
PHARMACOPOEI
A DEVICE SIZE
(Metric / Ph. Eur.)
DESIGNATION | Device Minimum
Knot Tensile Strength | |
|-----------------------------------|---------------------------------------------------------------------------|-----------------------------------------|--------------------------|
| | | USP (kgf) | Metric /
Ph. Eur. (N) |
| 0 | 3.5 | 3.90 | 39.0 |
| 2-0 | 3 | 2.68 | 26.3 |
| 3-0 | 2 | 1.77 | 17.4 |
| 4-0 | 1.5 | 0.95 | 9.32 |
Table 2. Tensile StrengthComparison
Indications for Use:
STRATAFIX™ Spiral MONOCRYL™ Plus Bidirectional Knotless Tissue Control Device is indicated for use in soft tissue approximation where the use of absorbable sutures is appropriate.
Performance Data:
Non-clinical laboratory performance testing was performed demonstrating that STRATAFIX™ Spiral MONOCRYL™ Plus Bidirectional Knotless Tissue Control Device conforms to the current USP Monograph for absorbable surgical sutures, except for diameter. The testing was performed in accordance with FDA's Guidance Document: "Class II Special Controls Guidance Document: Surgical Sutures" issued on June 3, 2003. Bench testing evaluated: Suture Diameter, Needle Attachment Strength, Tensile Strength, In Vitro Breaking Strength, and Ex Vivo Wound Closure Strength.
Summary of Technological Characteristics and Performance Testing:
The STRATAFIX™ Spiral MONOCRYL™ Plus Bidirectional Knotless Tissue Control Device has similar technological characteristics as the predicate devices. Like the currently marketed predicate devices, STRATAFIX™ Spiral MONOCRYL™ Plus Bidirectional Knotless Tissue Control Device is a sterile, monofilament synthetic absorbable suture intended for the approximation of soft tissue that conforms to the USP Monograph for absorbable surgical sutures, except for diameter. The STRATAFIX™ Spiral MONOCRYL™ Plus Bidirectional Knotless Tissue Control Device consists of barbed suture material, armed with a surgical needle on each end. The barbs in STRATAFIX™ Spiral MONOCRYL™ Plus Bidirectional Device allow the tissue approximation without the need to tie surgical knots.
STRATAFIX™ Spiral MONOCRYLTM Plus Bidirectional Knotless Tissue Control Device will be available as a suture product with IRGACARE ® MP, an antibacterial agent same as STRATAFIX™ Spiral MONOCRYL™ Plus Unidirectional predicate device.
6
Substantial Equivalence:
STRATAFIX™ Spiral MONOCRYLTM Plus Bidirectional Knotless Tissue Control Device has the same intended use and indication for use as the predicate devices. The technological differences between the subject device - STRATAFIX™ Spiral MONOCRYL™ Plus Bidirectional Knotless Tissue Control Device and the predicate devices raise no new questions of safety or effectiveness. STRATAFIX™ Spiral MONOCRYL™ Plus Bidirectional Knotless Tissue Control Device meets all testing criteria to demonstrate substantial equivalence to the predicates devices.
Conclusion:
Based on the intended use, technological characteristics, safety and performance testing STRATAFIX™ Spiral MONOCRYL™ Plus Bidirectional Knotless Tissue Control Device has been shown to be appropriate for its intended use and is considered to be substantially equivalent to the predicate devices.